Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. B, 13-18
© 1999 The British Society for Antimicrobial Chemotherapy
Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates
University Clinic for Internal Medicine I, Clinical Department for Infectious Diseases and Chemotherapy, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria
Antibiotic resistance among Streptococcus pneumoniae isolates has spread rapidly
throughout the world since the first description of a strain with diminished susceptibility to
penicillin in Australia in 1967. A total of 1385 strains of S. pneumoniae, collected in
several centres throughout Austria, were assessed for their sensitivity to moxifloxacin,
trovafloxacin, ciprofloxacin, ofloxacin, levofloxacin and lomefloxacin. The MICs were
determined
using the agar dilution method, according to NCCLS guidelines. Both moxifloxacin and
trovafloxacin showed good anti-pneumococcal activity in terms of MIC
50 (both 0.125 mg/L) and MIC
90 (both 0.25 mg/L). Less active, but with similar activity to each other, were
ciprofloxacin and levofloxacin, each with an MIC
50 of 1 mg/L and an MIC
90 of 2 mg/L. Ofloxacin showed only moderate activity (MIC
50, 1 mg/L; MIC
90, 2 mg/L) and lomefloxacin was the least active compound (MIC
50, 4 mg/L; MIC
90, 8 mg/L). Both moxifloxacin and trovafloxacin at a concentration of 
0.5
mg/L
inhibited all of the S.
pneumoniae strains tested.
* Corresponding author. Tel: +43-1-40400-5139; Fax: +43-1-40400-5167; E-mail: Apostopolos.Georgopoulos{at}akh-wien.ac.at
A. Hirschl, D. Wolf, W. Ulrich, U. Setinek-Liszka, C.
Moser, U.
Straschil, B. Bibus (Vienna); F. Allerbeger (Innsbruck); B. Sixl, W. Thiel (Graz); M.
Müller
(Salzburg); E. Grund (Klagenfurt); G. Alpi (Villach); G. Leitner (Leoben); W. Pfanzl
(Oberwart);
W. Aichinger (Wels); J. Feichtinger (Steyr); H. Gogl (Vöcklabruck); G. Brinninger (Ried);
W.
Öhlinger (Krems); L. Gerstner (Mistelbach); H. Hudler (Wr. Neustadt); M. Drlicek (Linz);
H.
Bankl (St. Pölten).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. M. Olsen, M. Gentry-Nielsen, M. Yue, M. U. Snitily, and L. C. Preheim Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia Antimicrob. Agents Chemother., January 1, 2006; 50(1): 210 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuhrmann, P. Schenk, W. Jaeger, S. Ahmed, and F. Thalhammer Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration J. Antimicrob. Chemother., October 1, 2004; 54(4): 780 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rendi-Wagner, A. Georgopoulos, M. Kundi, I. Mutz, M. Mattauch, J. Nowak, A. Mikolasek, A. Vecsei, and H. Kollaritsch Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria J. Antimicrob. Chemother., May 1, 2004; 53(5): 826 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Zinner, I. Yu. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing J. Antimicrob. Chemother., October 1, 2003; 52(4): 616 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Buxbaum, S. Forsthuber, W. Graninger, and A. Georgopoulos Comparative activity of telithromycin against typical community-acquired respiratory pathogens J. Antimicrob. Chemother., September 1, 2003; 52(3): 371 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Houssaye, L. Gutmann, and E. Varon Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2712 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Grif, M. P. Dierich, K. Pfaller, P. A. Miglioli, and F. Allerberger In vitro activity of fosfomycin in combination with various antistaphylococcal substances J. Antimicrob. Chemother., August 1, 2001; 48(2): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, R. C. George, and D. M. Livermore Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales J. Antimicrob. Chemother., April 1, 2001; 47(4): 411 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Jones, A. M. Staples, I. Critchley, C. Thornsberry, P. Heinze, H. D. Engler, and D. F. Sahm Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2645 - 2652. [Abstract] [Full Text]
|
|